CN104717976A - 嵌合ksac蛋白的表达和由高压产生可溶性蛋白的方法 - Google Patents

嵌合ksac蛋白的表达和由高压产生可溶性蛋白的方法 Download PDF

Info

Publication number
CN104717976A
CN104717976A CN201380053720.8A CN201380053720A CN104717976A CN 104717976 A CN104717976 A CN 104717976A CN 201380053720 A CN201380053720 A CN 201380053720A CN 104717976 A CN104717976 A CN 104717976A
Authority
CN
China
Prior art keywords
bar
protein
composition
high pressure
inclusion bodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380053720.8A
Other languages
English (en)
Chinese (zh)
Inventor
L·B·菲舍
N·P·Y·卡尔布莱克
F·卢克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merial Ltd
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd filed Critical Merial Ltd
Priority to CN201810318137.XA priority Critical patent/CN108578679A/zh
Publication of CN104717976A publication Critical patent/CN104717976A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B2/00—Preservation of foods or foodstuffs, in general
    • A23B2/10—Preservation of foods or foodstuffs, in general by treatment with pressure variation, shock, acceleration or shear stress
    • A23B2/103—Preservation of foods or foodstuffs, in general by treatment with pressure variation, shock, acceleration or shear stress using sub- or super-atmospheric pressures, or pressure variations transmitted by a liquid or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01041—Sterol 24-C-methyltransferasee (2.1.1.41)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Sustainable Development (AREA)
CN201380053720.8A 2012-08-30 2013-08-30 嵌合ksac蛋白的表达和由高压产生可溶性蛋白的方法 Pending CN104717976A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810318137.XA CN108578679A (zh) 2012-08-30 2013-08-30 嵌合ksac蛋白的表达和由高压产生可溶性蛋白的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261694968P 2012-08-30 2012-08-30
US61/694,968 2012-08-30
US201361830425P 2013-06-03 2013-06-03
US61/830,425 2013-06-03
PCT/US2013/057430 WO2014036349A1 (en) 2012-08-30 2013-08-30 Expression of chimeric ksac protein and method of producing soluble proteins by high pressure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810318137.XA Division CN108578679A (zh) 2012-08-30 2013-08-30 嵌合ksac蛋白的表达和由高压产生可溶性蛋白的方法

Publications (1)

Publication Number Publication Date
CN104717976A true CN104717976A (zh) 2015-06-17

Family

ID=49162270

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201380054922.4A Active CN104768577B (zh) 2012-08-30 2013-08-30 高压设备和用于制备灭活疫苗和用于重折叠/增溶重组蛋白的方法
CN201810318137.XA Pending CN108578679A (zh) 2012-08-30 2013-08-30 嵌合ksac蛋白的表达和由高压产生可溶性蛋白的方法
CN201380053720.8A Pending CN104717976A (zh) 2012-08-30 2013-08-30 嵌合ksac蛋白的表达和由高压产生可溶性蛋白的方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201380054922.4A Active CN104768577B (zh) 2012-08-30 2013-08-30 高压设备和用于制备灭活疫苗和用于重折叠/增溶重组蛋白的方法
CN201810318137.XA Pending CN108578679A (zh) 2012-08-30 2013-08-30 嵌合ksac蛋白的表达和由高压产生可溶性蛋白的方法

Country Status (18)

Country Link
US (3) US9315553B2 (enExample)
EP (2) EP2890393A2 (enExample)
JP (2) JP6405308B2 (enExample)
KR (1) KR102208844B1 (enExample)
CN (3) CN104768577B (enExample)
AP (1) AP2015008331A0 (enExample)
AU (4) AU2013308627B2 (enExample)
BR (1) BR112015004463B8 (enExample)
CA (2) CA2883296A1 (enExample)
EA (1) EA031988B1 (enExample)
ES (1) ES2744709T3 (enExample)
HK (1) HK1211874A1 (enExample)
MD (1) MD4608C1 (enExample)
MX (3) MX381717B (enExample)
NZ (3) NZ706288A (enExample)
PH (1) PH12015500700B1 (enExample)
RU (1) RU2647568C2 (enExample)
WO (2) WO2014036349A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968749B2 (en) * 2006-07-21 2015-03-03 Universidade Federal De Minas Gerais—Ufmg Vaccine composition and immunization method
ZA201501696B (en) 2012-08-30 2016-01-27 Merial Ltd Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins
NZ706288A (en) * 2012-08-30 2016-06-24 Merial Inc Expression of chimeric ksac protein and method of producing soluble proteins by high pressure
ES2728865T3 (es) * 2013-03-28 2019-10-29 Infectious Disease Res Inst Vacunas que comprenden polipéptidos de Leishmania para el tratamiento y el diagnóstico de la leishmaniasis
CN104758944B (zh) 2015-04-02 2017-11-28 中国科学院过程工程研究所 一种疫苗制剂及其制备方法和用途
JP2018082987A (ja) * 2016-11-25 2018-05-31 株式会社日立製作所 ウイルス不活化方法及びウイルス不活化装置
JP2020152644A (ja) * 2019-03-18 2020-09-24 国立大学法人愛媛大学 Ｖｎａｒのリフォールディング方法およびｖｎａｒの製造方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN112120012B (zh) * 2020-09-30 2022-03-22 广东康盾创新产业集团股份公司 一种car-t细胞冻存方法
BR102021000794A2 (pt) * 2021-01-15 2022-07-26 Fundação Oswaldo Cruz Proteína quimérica, kit, método para diagnóstico de leishmaniose, uso de uma proteína quimérica, composição vacinal contra leishmaniose visceral, e, uso de uma composição vacinal

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062827A2 (en) * 2000-10-31 2002-08-15 The Regents Of The University Of Colorado, A Body Corporate Improved protein disaggregation and refolding using high pressure
WO2009143006A1 (en) * 2008-05-21 2009-11-26 Infectious Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
JP2743177B2 (ja) * 1987-04-24 1998-04-22 財団法人阪大微生物病研究会 百日咳菌の培養方法、及び百日咳トキソイドとその混合ワクチン
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US5980912A (en) 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
FR2771011B1 (fr) 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves
AU4975699A (en) 1998-07-09 2000-02-01 University Technology Corporation High pressure refolding of protein aggregates and inclusion bodies
WO2000072703A1 (en) 1999-05-28 2000-12-07 UNIVERSITé LAVAL Inactivation of food spoilage and pathogenic microorganisms by dynamic high pressure
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
UA77152C2 (en) 1999-09-25 2006-11-15 Method for stimulation of immune response using nucleic acid-containing immunostimulating compositions, method for treatment of cancer and method for treatment or prophylaxis of allergy or asthma
US7615617B2 (en) 1999-10-25 2009-11-10 University Of Delaware Use of hydrostatic pressure to inhibit and reverse protein aggregation and facilitate protein refolding
AU2002246493A1 (en) 2000-08-10 2002-07-30 Boston Biomedica, Inc. Pressure cycling inactivation of pathogens in biological materials used for therapeutics or vaccines
US6635223B2 (en) * 2000-10-25 2003-10-21 Andreas Maerz Method for inactivating micro-organisms using high pressure processing
WO2004024027A2 (en) 2002-06-07 2004-03-25 University Of Florida Endodontic files made using bulk metallic glasses
SE525457C2 (sv) 2002-06-24 2005-02-22 Flow Holdings Sagl Förfarande för åstadkommande av en tryckändring mellan två trycktillstånd, högtryckspressanordning samt användning av förfarande eller högtryckspressanordning
WO2005044301A2 (en) * 2003-11-05 2005-05-19 C.B.F. Leti, S.L. Unipersonal Use of specific histones for the treatment of parasitic diseases
US7993580B2 (en) 2004-08-24 2011-08-09 Baxter International Inc. Methods for the inactivation of microorganisms in biological fluids, flow through reactors and methods of controlling the light sum dose to effectively inactivate microorganisms in batch reactors
EP1971435A2 (en) 2005-11-21 2008-09-24 BaroFold, Inc. Devices and methods for high-pressure refolding of proteins
CN200945252Y (zh) * 2006-09-01 2007-09-12 天津市华泰森淼生物工程技术有限公司 手动开启式小型超高压生物处理设备
WO2008033556A2 (en) * 2006-09-15 2008-03-20 Barofold, Inc. High pressure treatment of proteins for reduced immunogenicity
US7829681B2 (en) * 2007-04-05 2010-11-09 Barofold Inc. High-pressure inclusion body solubilization and protease clipping of recombinant fusion proteins
US20080249286A1 (en) 2007-04-05 2008-10-09 Seefeldt Matthew B High-pressure refolding of proteins in the presence of binding partners
EP2207890A4 (en) 2007-10-05 2010-12-15 Barofold Inc HIGH PRESSURE PROCESSING OF AGGREGATED INTERFERONS
PT2224951T (pt) * 2007-12-21 2020-01-10 Zoetis Services Llc Bacterinas tratadas termicamente e vacinas de emulsão preparadas a partir de tais bacterinas tratadas termicamente
BRPI0800357A2 (pt) 2008-03-10 2009-10-27 Fundacao Oswaldo Cruz método para produção de uma vacina estabilizada
CN102066411A (zh) 2008-05-08 2011-05-18 梅里亚有限公司 使用白蛉唾液免疫原的利什曼原虫疫苗
US8410258B2 (en) * 2008-05-21 2013-04-02 Infections Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
US20100112660A1 (en) 2008-05-30 2010-05-06 Barofold, Inc. Method for Derivatization of Proteins Using Hydrostatic Pressure
US20110070219A1 (en) 2009-04-27 2011-03-24 Seefeldt Matthew B High pressure protein crystallization
EP2531042A1 (en) * 2010-02-01 2012-12-12 Avure Technologies AB High-pressure arrangement with locking element preventing rotation of load basket
CN201781934U (zh) * 2010-04-14 2011-04-06 中国农业大学 一种小型框架自动式超高压设备
ES2749977T3 (es) 2010-07-19 2020-03-24 Pressure Biosciences Inc Composiciones de proteínas terapéuticas que tienen inmunogenia reducida y/o eficacia mejorada
ZA201501696B (en) * 2012-08-30 2016-01-27 Merial Ltd Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins
NZ706288A (en) 2012-08-30 2016-06-24 Merial Inc Expression of chimeric ksac protein and method of producing soluble proteins by high pressure

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062827A2 (en) * 2000-10-31 2002-08-15 The Regents Of The University Of Colorado, A Body Corporate Improved protein disaggregation and refolding using high pressure
WO2009143006A1 (en) * 2008-05-21 2009-11-26 Infectious Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MATTHEW B. SEEFELDT: "High-pressure refolding of bikunin：Efficacy and thermodynamics", 《PROTEIN SCIENCE》 *
WALID QORONFLEH等: "Confronting high-throughput protein refolding using high pressure and solution screens", 《PROTEIN EXPRESSION AND PURIFICATION》 *

Also Published As

Publication number Publication date
JP6405308B2 (ja) 2018-10-17
BR112015004463B8 (pt) 2022-06-28
EP2890392B1 (en) 2019-04-17
MX2015002701A (es) 2015-12-01
US20140072594A1 (en) 2014-03-13
MX381717B (es) 2025-03-13
US20140065187A1 (en) 2014-03-06
AU2013308627B2 (en) 2016-10-27
US10364274B2 (en) 2019-07-30
EP2890392A1 (en) 2015-07-08
JP6438396B2 (ja) 2018-12-12
WO2014036345A3 (en) 2014-06-26
MX2021004478A (es) 2021-06-04
EA031988B1 (ru) 2019-03-29
RU2647568C2 (ru) 2018-03-16
BR112015004463B1 (pt) 2021-08-24
AU2017200301A1 (en) 2017-02-16
BR112015004463A2 (pt) 2017-08-08
HK1211874A1 (zh) 2016-06-03
US9315553B2 (en) 2016-04-19
JP2015528466A (ja) 2015-09-28
EA201500275A1 (ru) 2015-07-30
JP2015529462A (ja) 2015-10-08
PH12015500700A1 (en) 2015-05-25
CN108578679A (zh) 2018-09-28
HK1211873A1 (en) 2016-06-03
NZ706288A (en) 2016-06-24
ES2744709T3 (es) 2020-02-26
CA2883303A1 (en) 2014-03-06
WO2014036345A2 (en) 2014-03-06
AU2013308627A1 (en) 2015-04-09
KR102208844B1 (ko) 2021-01-27
AU2013308623B2 (en) 2017-03-02
AU2013308623A1 (en) 2015-04-02
AU2017201724A1 (en) 2017-03-30
CA2883296A1 (en) 2014-03-06
US9169302B2 (en) 2015-10-27
PH12015500700B1 (en) 2018-11-28
EP2890393A2 (en) 2015-07-08
MD4608B1 (ro) 2018-12-31
CN104768577B (zh) 2020-06-09
AU2017201724B2 (en) 2019-01-17
MD20150031A2 (ro) 2015-10-31
WO2014036349A1 (en) 2014-03-06
KR20150063403A (ko) 2015-06-09
CN104768577A (zh) 2015-07-08
US20170081372A1 (en) 2017-03-23
MX2015002699A (es) 2015-12-01
NZ705790A (en) 2016-06-24
MD4608C1 (ro) 2019-07-31
MX358782B (es) 2018-09-04
AP2015008331A0 (en) 2015-03-31
RU2015111255A (ru) 2016-10-20
NZ715459A (en) 2017-05-26

Similar Documents

Publication Publication Date Title
CN104717976A (zh) 嵌合ksac蛋白的表达和由高压产生可溶性蛋白的方法
US20220105170A1 (en) African swine fever vaccine
US10363300B2 (en) FMDV and E2 fusion proteins and uses thereof
CN106540248B (zh) 一种抗口蹄疫的疫苗组合物及其制备方法和应用
WO2017011918A1 (en) Mycoplasma bovis vaccines and uses thereof
CN111944024B (zh) 口蹄疫病毒样颗粒、制备方法、疫苗组合物和应用
CN105624124B (zh) 一种抗o型口蹄疫的疫苗组合物及其制备方法和应用
CN105821011B (zh) 一种抗o型口蹄疫的疫苗组合物及其制备和应用
JP2023520803A (ja) 口蹄疫ウイルス様粒子抗原、及びそのワクチン組成物、調製方法と使用
HK1211873B (en) Expression of chimeric ksac protein and method of producing soluble proteins by high pressure
US11000579B2 (en) Recombinant Eimeria maxima protein delivered as nanoparticles
CN117979989A (zh) 针对蠕虫的兽用疫苗组合物、用于治疗和预防由蠕虫引起的感染的方法和用途
CZ292879B6 (cs) DNA vakcína proti houbovým infekcím, zejména trichofytóze

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150617